Katarzyna M.
- Country
- Poland
- Department
- -
Research Overview
- Evaluation of Ofatumumab Efficacy and Patient-Reported Outcomes in Relapsing Multiple Sclerosis Patients Transitioning from Fumarate-Based Therapies or Fingolimod
- Long-term Safety and Efficacy Evaluation of Ocrelizumab in Multiple Sclerosis Patients from Phase III Studies
- Phase 3 Randomized, Double-Blind Study of Frexalimab (SAR441344) Versus Teriflunomide in Adults with Relapsing Multiple Sclerosis
Data & Insights
Has run more than one trial at 220 of 416 partner sites.
Specializations
Multiple Sclerosis Research
This investigator specializes in evaluating novel therapeutic approaches for multiple sclerosis, with particular focus on both relapsing and progressive forms of the disease.
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
The investigator's work encompasses evaluation of innovative treatments including monoclonal antibodies and targeted molecular therapies.
Neurological Assessment
Expertise in analyzing neurological biomarkers and advanced imaging techniques for monitoring disease progression and treatment efficacy.
- Brain Atrophy Measurement
- Neurofilament Level Analysis
- MRI-based Disease Monitoring
Focus includes evaluation of disability progression and neurological function assessment.
Treatment Innovation
Active involvement in investigating emerging therapeutic agents for neurological conditions, particularly in comparative efficacy studies.
- Novel Drug Development
- Long-term Safety Assessment
- Treatment Optimization Strategies
Specialized in evaluating therapeutic transitions and combination treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.